“A major concern raised regarding these tests is the possibility they will lead to high levels of anxiety in consumers who receive estimates of high genetic risk,” said Cinnamon Bloss, STSI clinical psychologist and lead author of the article. “But our data suggest this is not the case.”...
Alzheimer's Reading Room
This is actually good news for those hoping for a treatment or cure for Alzheimer's disease. In order to find a treatment scientist will need to find candidates that are predisposed to Alzheimer's disease or in any early stage -- like mild cognitive impairment. In this way, a gene therapy or drug based on these genes might be developed.
If people are willing to get tested, they are also likely to volunteer for participation in a clinical trial.
Rudi Tanzi talked about the path to a treatment for Alzheimer's disease in this Alzheimer's Reading Room podcast -- The Plan to End Alzheimer's Disease by 2020 (Podcast).
Scripps Study First to Assess Consumer Impact of Personal Genetic Tests
Study shows tests don’t cause anxiety; and, do spark interest in health screenings
New findings from a landmark research study led by Scripps Health and the Scripps Translational Science Institute (STSI) reveal that personal genetic tests have some promising effects on consumers who choose to undergo the screenings. STSI is an initiative of Scripps Health in collaboration with The Scripps Research Institute.
Initial results from the Scripps Genomic Health Initiative (SGHI) published in an article on the New England Journal of Medicine’s website, www.nejm.org. Launched in October 2008, SGHI is the first scientific study to assess how these tests, which have been mired in controversy, affect consumers’ health and well-being.
The SGHI study found no evidence that the screenings induced psychological anxiety among its 2,037 participants. The study also found that among those participants whose scans showed a high risk for developing a disease, a significant proportion expressed strong intent to undergo the corresponding health screening test.
Study participants who were age 18 and older received a scan of their genome for more than 20 health conditions that may be changed by health screening and lifestyle, including diabetes, obesity, heart attack and some forms of cancer. The study will assess changes in participants’ behavior over an extended period of up to 20 years.
“A major concern raised regarding these tests is the possibility they will lead to high levels of anxiety in consumers who receive estimates of high genetic risk,” said Cinnamon Bloss, STSI clinical psychologist and lead author of the article. “But our data suggest this is not the case.”
While the study revealed some promising findings, Bloss said SGHI failed to find evidence of improved lifestyle among participants, such as increased exercise or lower fat intake. “This was not necessarily surprising, however, given how difficult it is to both measure, as well as affect behavior change in these areas,” she said.
Before receiving their genome scan results, SGHI participants completed a self-reported baseline questionnaire to gauge their individual level of anxiety, exercise and eating habits, medical screening practices and other behaviors. Results in the New England Journal of Medicine article are based on a comparison between participants’ baseline surveys and their follow-up assessments, which were completed five to six months after they received their gene scan results.
“Our evaluations of participants’ responses to genetic testing at five or so months sets the stage for us to further study their responses after one year, since this timeframe would provide opportunity to initiate and sustain changes in health behaviors if five months wasn’t long enough,” said Nicholas Schork, professor at The Scripps Research Institute and director of biostatistics and bioinformatics with STSI.
Additionally, 26.5 percent of participants reported sharing their results with their physician, and doing so was associated with behavior change such as lower fat intake and increased exercise. A recent survey shows only about 10 percent of physicians feel they have the necessary training and education in genomics to provide patient care in this area, highlighting a void with respect to physician knowledge and education.
SGHI is sponsored by STSI and the National Institutes of Health’s flagship Clinical and Translational Science Award grant, which was awarded to The Scripps Research Institute, which then partnered with STSI. Additional support comes from a developmental grant from the National Human Genome Research Institute and the Scripps Genomic Medicine division of Scripps Health. SGHI includes a collaboration axis of three companies, which provided no financial assistance to the study: Navigenics Inc. of Foster City, Calif.; Affymetrix of Santa Clara, Calif.; and Microsoft Corp. of Redmond, Wash.
About Scripps Translational Science Institute
Founded in 2006, Scripps Translational Science Institute (STSI) is an initiative of Scripps Health, in collaboration with The Scripps Research Institute. STSI initiates research designed to help move basic research from the lab to the patient bedside, bridging the gap between basic science and clinical trials. Scripps Genomic Medicine is a program of STSI and involves genotyping tens of thousands of individuals to identify and define genes responsible for major diseases and the underpinnings of health.
About Scripps Health
Founded in 1924 by philanthropist Ellen Browning Scripps, Scripps Health is a $2.3 billion, private not-for-profit integrated health system based in San Diego, Calif. Scripps treats a half-million patients annually through the dedication of 2,500 affiliated physicians and 13,000 employees among its five acute-care hospital campuses, home health care services, and ambulatory care network of physician offices and 22 outpatient centers and clinics.
Recognized as a leader in the prevention, diagnosis, and treatment of disease, Scripps is also at the forefront of clinical research, genomic medicine, wireless health care and graduate medical education. Scripps has been recognized by Thomson Reuters as one of the Top 10 health systems in the nation for quality care. With three highly respected graduate medical education programs, Scripps is a longstanding member of the Association of American Medical Colleges. More information can be found at www.scripps.org.
About The Scripps Research Institute
The Scripps Research Institute is one of the world’s largest independent, non-profit biomedical research organizations, at the forefront of basic biomedical science that seeks to comprehend the most fundamental processes of life. Scripps Research is internationally recognized for its discoveries in immunology, molecular and cellular biology, chemistry, neurosciences, autoimmune, cardiovascular, and infectious diseases, and synthetic vaccine development.
An institution that evolved from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps in 1924, Scripps Research currently employs approximately 3,000 scientists, postdoctoral fellows, scientific and other technicians, doctoral degree graduate students, and administrative and technical support personnel. Headquartered in La Jolla, Calif., the institute also includes Scripps Florida, whose researchers focus on basic biomedical science, drug discovery, and technology development. Scripps Florida is located in Jupiter, Fla. For more information, see www.scripps.edu.
Alzheimer's Disease -- Advice and Insight
- What’s the Difference Between Alzheimer’s Disease and Dementia?
- 60 Good Reasons to Subscribe to the Alzheimer's Reading Room
- About the Alzheimer's Reading Room
- Alzheimer's Disease and the Five Stages of Grief
- What is Alzheimer's? What are the Eight Types of Dementia?
- Alzheimer's Disease CareGiving -- Insight and Advice (20 articles)
- Test Your Memory for Alzheimer's Disease (5 Best Self Assessment Tests)
- Alzheimer's World -- Trying to Reconnect with Someone Suffering from Alzheimer's Disease
- Worried About Alzheimer's Disease -- You Should Be
- Does the Combination of Aricept and Namenda Help Slow the Rate of Decline in Alzheimer's Disease Patients
- Alzheimer's Disease Statistics
- Is it Really Alzheimer's Disease or Something Else?
- Ten Symptoms of Early Stage Alzheimer's Disease
- Ten Tips for Communicating with an Alzheimer’s Disease Patients
Original content Bob DeMarco, the Alzheimer's Reading Room